[go: up one dir, main page]

WO2007047504A3 - Natriuretic peptide modified transferrin fusion proteins - Google Patents

Natriuretic peptide modified transferrin fusion proteins Download PDF

Info

Publication number
WO2007047504A3
WO2007047504A3 PCT/US2006/040207 US2006040207W WO2007047504A3 WO 2007047504 A3 WO2007047504 A3 WO 2007047504A3 US 2006040207 W US2006040207 W US 2006040207W WO 2007047504 A3 WO2007047504 A3 WO 2007047504A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
natriuretic peptide
peptide modified
transferrin fusion
modified transferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040207
Other languages
French (fr)
Other versions
WO2007047504A2 (en
Inventor
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Priority to EP06825957A priority Critical patent/EP1951277A2/en
Priority to CA002625600A priority patent/CA2625600A1/en
Priority to JP2008535740A priority patent/JP2009511060A/en
Publication of WO2007047504A2 publication Critical patent/WO2007047504A2/en
Publication of WO2007047504A3 publication Critical patent/WO2007047504A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Fusion proteins of transferrin and natriuretic peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
PCT/US2006/040207 2005-10-14 2006-10-16 Natriuretic peptide modified transferrin fusion proteins Ceased WO2007047504A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06825957A EP1951277A2 (en) 2005-10-14 2006-10-16 Natriuretic peptide modified transferrin fusion proteins
CA002625600A CA2625600A1 (en) 2005-10-14 2006-10-16 Natriuretic peptide modified transferrin fusion proteins
JP2008535740A JP2009511060A (en) 2005-10-14 2006-10-16 Natriuretic peptide modified transferrin fusion protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72619805P 2005-10-14 2005-10-14
US60/726,198 2005-10-14

Publications (2)

Publication Number Publication Date
WO2007047504A2 WO2007047504A2 (en) 2007-04-26
WO2007047504A3 true WO2007047504A3 (en) 2007-06-14

Family

ID=37963135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040207 Ceased WO2007047504A2 (en) 2005-10-14 2006-10-16 Natriuretic peptide modified transferrin fusion proteins

Country Status (4)

Country Link
EP (1) EP1951277A2 (en)
JP (1) JP2009511060A (en)
CA (1) CA2625600A1 (en)
WO (1) WO2007047504A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689492A1 (en) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
EP2195028A2 (en) 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
KR101768661B1 (en) * 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 Novel NPR-B Agonists
AR078446A1 (en) 2009-12-18 2011-11-09 Alcon Res Ltd NPR-B AGONISTS. USE.
WO2012019237A1 (en) 2010-08-12 2012-02-16 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
TW201442721A (en) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd Glycosilated atrial natriuretic peptide
HK1222331A1 (en) 2013-03-12 2017-06-30 通用医疗公司 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
DK2970429T3 (en) 2013-03-15 2019-11-18 Gladiator Biosciences Inc GLA DOMAINS AS A TARGET
ES2912283T3 (en) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Use of müllerian inhibitory substance (MIS)-type proteins for contraception and preservation of ovarian reserve
AU2015243961A1 (en) 2014-04-10 2016-10-27 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
CN117157314A (en) * 2020-09-16 2023-12-01 苏州逻晟生物医药有限公司 PD-L1 antibodies, fusion proteins and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403336B1 (en) * 1985-06-20 2002-06-11 Fujisawa Pharmaceutical Co., Ltd. Process for the production of α-human atrial natriuretic polypeptide
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US6987088B2 (en) * 1999-07-02 2006-01-17 Genentech, Inc. Compounds that bind HER2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403336B1 (en) * 1985-06-20 2002-06-11 Fujisawa Pharmaceutical Co., Ltd. Process for the production of α-human atrial natriuretic polypeptide
US6987088B2 (en) * 1999-07-02 2006-01-17 Genentech, Inc. Compounds that bind HER2
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI H. ET AL.: "Transferrin/Transferrin Receptor-Mediated Drug Delivery", MEDICINAL RESEARCH REVIEWS, vol. 22, no. 3, pages 225 - 250, XP003014317 *
WANG W. ET AL.: "AlbuBNP, a Recombinant B-Type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure", PHARM. RES., vol. 21, no. 11, 2004, pages 2105 - 2110, XP003014318 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US10941215B2 (en) 2010-11-30 2021-03-09 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses thereof

Also Published As

Publication number Publication date
CA2625600A1 (en) 2007-04-26
JP2009511060A (en) 2009-03-19
EP1951277A2 (en) 2008-08-06
WO2007047504A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
WO2004020405A3 (en) Modified transferrin fusion proteins
IL160289A0 (en) Modified transferrin fusion proteins
WO2004020454A3 (en) Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
EP2949658A3 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
WO2006061219A3 (en) Il-7 variants with reduced immunogenicity
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
WO2006130834A3 (en) IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2007009018A3 (en) Il-6 binding proteins
WO2004020588A3 (en) Transferrin fusion protein libraries
WO2006049983A3 (en) Peptide yy modified transferrin fusion proteins
WO2006076742A3 (en) Methods and compositions for increasing membrane permeability
WO2008021412A3 (en) Interferon beta and transferrin fusion proteins
WO2003020759A3 (en) A caspase- 8 binding protein, its preparation and use
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
WO2004033694A3 (en) Promoter to il-18bp, its preparation and use
WO2006123157A3 (en) Nematistatic protein
WO2007002510A3 (en) A system and method to obtain oligo-peptides with specific high affinity to query proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2625600

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008535740

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006825957

Country of ref document: EP